Literature DB >> 18833030

A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh.

Fahima Chowdhury1, Ashraful I Khan, Jason B Harris, Regina C LaRocque, Mohiul Islam Chowdhury, Edward T Ryan, A S G Faruque, Stephen B Calderwood, Firdausi Qadri.   

Abstract

BACKGROUND: : Infection with Vibrio cholerae induces protection from subsequent severe disease, suggesting that an effective vaccine could be an important preventive strategy. Available vaccines provide less protection against cholera than natural infection, particularly in children.
METHODS: : We examined a cohort of 121 children (2 years-12 years of age) and 276 older patients (>12 years of age) hospitalized with cholera in Dhaka, Bangladesh over a 4-year period, to compare clinical features in older patients and children and immune responses to key antigens.
RESULTS: : Older patients had more severe disease. Children with cholera were more commonly retinol deficient, while zinc deficiency was equally prevalent in both groups. Children developed higher vibriocidal and serum immune responses to the B subunit of cholera toxin (CTB). In contrast, older patients mounted higher immune responses to 2 other key V. cholerae antigens, the lipopolysaccharide (LPS) and toxin coregulated pilus antigens (TcpA). We compared immune responses following infection with those occurring after receipt of a live, oral vaccine in both children and older patients in Bangladesh, during a similar time period. The response rates for vibriocidal and LPS antibodies were higher after infection than after vaccination. Both vaccinated older patients and children responded poorly to CTB and TcpA.
CONCLUSIONS: : Although children developed vigorous vibriocidal and CTB-specific responses following infection, they had lessened responses to LPS and TcpA compared with older patients, as well as lessened responses to vaccination. More studies need to be carried out to determine factors, including micronutrient interventions that can improve responses in children to both natural infection and vaccination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18833030      PMCID: PMC2749325          DOI: 10.1097/INF.0b013e3181783adf

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  35 in total

1.  Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.

Authors:  D N Taylor; V Cárdenas; J Perez; R Puga; A M Svennerholm
Journal:  Am J Trop Med Hyg       Date:  1999-12       Impact factor: 2.345

2.  Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine.

Authors:  M John Albert; Firdausi Qadri; Mohammad A Wahed; Tanvir Ahmed; A S M Hamidur Rahman; Firoz Ahmed; Nurul A Bhuiyan; K Zaman; Abdullah H Baqui; John D Clemens; Robert E Black
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

3.  Epidemic and endemic cholera trends over a 33-year period in Bangladesh.

Authors:  Ira M Longini; Mohammed Yunus; K Zaman; A K Siddique; R Bradley Sack; Azhar Nizam
Journal:  J Infect Dis       Date:  2002-06-17       Impact factor: 5.226

4.  Effectiveness of mass oral cholera vaccination in Beira, Mozambique.

Authors:  Marcelino E S Lucas; Jacqueline L Deen; Lorenz von Seidlein; Xuan-Yi Wang; Julia Ampuero; Mahesh Puri; Mohammad Ali; M Ansaruzzaman; Juvenaldo Amos; Arminda Macuamule; Philippe Cavailler; Philippe J Guerin; Claude Mahoudeau; Pierre Kahozi-Sangwa; Claire-Lise Chaignat; Avertino Barreto; Francisco F Songane; John D Clemens
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

5.  A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized and control populationd of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate.

Authors:  W H Mosley; A S Benenson; R Barui
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

6.  The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139.

Authors:  Muhammad Asaduzzaman; Edward T Ryan; Manohar John; Long Hang; Ashraful I Khan; A S G Faruque; Ronald K Taylor; Stephen B Calderwood; Firdausi Qadri
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

7.  Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine.

Authors:  Firdausi Qadri; Tanvir Ahmed; Mohammad A Wahed; Firoz Ahmed; Nurul A Bhuiyan; A S M Hamidur Rahman; John D Clemens; Robert E Black; M John Albert
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

8.  Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers.

Authors:  Firdausi Qadri; Edward T Ryan; A S G Faruque; Firoz Ahmed; Ashraful Islam Khan; M Monirul Islam; Syed M Akramuzzaman; David A Sack; Stephen B Calderwood
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

9.  Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation.

Authors:  Tom H Karlsen; Halvor Sommerfelt; Skjalg Klomstad; Per Kragh Andersen; Tor A Strand; Rune J Ulvik; Christina Ahrén; Harleen M S Grewal
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

10.  A 4-year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh.

Authors:  R Bradley Sack; A Kasem Siddique; Ira M Longini; Azhar Nizam; Md Yunus; M Sirajul Islam; J Glenn Morris; Afsar Ali; Anwar Huq; G Balakrish Nair; Firdausi Qadri; Shah M Faruque; David A Sack; Rita R Colwell
Journal:  J Infect Dis       Date:  2002-12-13       Impact factor: 5.226

View more
  24 in total

1.  Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Mohammad Arif Rahman; M Mohasin; Sweta M Patel; Amena Aktar; Farhana Khanam; Taher Uddin; M Asrafuzzaman Riyadh; Amit Saha; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Richelle Charles; Regina LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 2.  Use of Pathogen-Specific Antibody Biomarkers to Estimate Waterborne Infections in Population-Based Settings.

Authors:  Natalie G Exum; Nora Pisanic; Douglas A Granger; Kellogg J Schwab; Barbara Detrick; Margaret Kosek; Andrey I Egorov; Shannon M Griffin; Christopher D Heaney
Journal:  Curr Environ Health Rep       Date:  2016-09

3.  Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera.

Authors:  Mohammad Murshid Alam; M Asrafuzzaman Riyadh; Kaniz Fatema; Mohammad Arif Rahman; Nayeema Akhtar; Tanvir Ahmed; Mohiul Islam Chowdhury; Fahima Chowdhury; Stephen B Calderwood; Jason B Harris; Edward T Ryan; Firdausi Qadri
Journal:  Clin Vaccine Immunol       Date:  2011-02-23

Review 4.  Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.

Authors:  Sachin N Desai; Alejandro Cravioto; Dipika Sur; Suman Kanungo
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 5.  Cholera.

Authors:  Jason B Harris; Regina C LaRocque; Firdausi Qadri; Edward T Ryan; Stephen B Calderwood
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

6.  The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.

Authors:  Leslie M Mayo-Smith; Jakub K Simon; Wilbur H Chen; Douglas Haney; Michael Lock; Caroline E Lyon; Stephen B Calderwood; Beth D Kirkpatrick; Mitchell Cohen; Myron M Levine; Marc Gurwith; Jason B Harris
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

7.  Vibrio cholerae El Tor TcpA crystal structure and mechanism for pilus-mediated microcolony formation.

Authors:  Mindy S Lim; Dixon Ng; ZuSheng Zong; Andrew S Arvai; Ronald K Taylor; John A Tainer; Lisa Craig
Journal:  Mol Microbiol       Date:  2010-06-01       Impact factor: 3.501

8.  Cholera caused by Vibrio cholerae O1 induces T-cell responses in the circulation.

Authors:  Taufiqur Rahman Bhuiyan; Samuel B Lundin; Ashraful Islam Khan; Anna Lundgren; Jason B Harris; Stephen B Calderwood; Firdausi Qadri
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

9.  Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1.

Authors:  Ashraful I Khan; Fahima Chowdhury; Jason B Harris; Regina C Larocque; Abu S G Faruque; Edward T Ryan; Stephen B Calderwood; Firdausi Qadri
Journal:  Scand J Infect Dis       Date:  2010

10.  Immunologic responses to Vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh.

Authors:  Jason B Harris; Michael J Podolsky; Taufiqur R Bhuiyan; Fahima Chowdhury; Ashraful I Khan; Regina C Larocque; Tanya Logvinenko; Jennifer Kendall; Abu S G Faruque; Cathryn R Nagler; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood
Journal:  PLoS Negl Trop Dis       Date:  2009-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.